Built from Align Technology, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
ALGN · Nasdaq · Healthcare · Medical Instruments and Supplies
$172.00-1.4%Nov 11 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Company outlook: revenue of $1B to $1B for Fiscal Q4 2026 — down 3.6% on a year earlier ($1B)
Just reported
From Align Technology's results release of October 28, 2026; its quarterly report has since been filed.
Actual
$1.01B
+1.9% y/y
-3.9% q/q
Guided
$1.01B
midpoint
Actual
$1.90
+144% y/y
+26% q/q
Guided
—
No guide given
Actual
$169.2M
+76% y/y
+9.8% q/q
Guided
—
No guide given
Q4 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The themes Align Technology is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Grade C
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Align Technology, Inc.’s grade history. The other 39 go back to November 2016.
